Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RNAC 
Cartesian Therapeutics Inc. (RNAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: RNAC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $36.43
1 Year Target Price $36.43
| 4 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.41% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 249.62M USD | Price to earnings Ratio - | 1Y Target Price 36.43 |
Price to earnings Ratio - | 1Y Target Price 36.43 | ||
Volume (30-day avg) 8 | Beta 0.83 | 52 Weeks Range 8.46 - 26.50 | Updated Date 09/17/2025 |
52 Weeks Range 8.46 - 26.50 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7319.13% |
Management Effectiveness
Return on Assets (TTM) -13.65% | Return on Equity (TTM) -7029.26% |
Valuation
Trailing PE - | Forward PE 25.45 | Enterprise Value 102644603 | Price to Sales(TTM) 243.29 |
Enterprise Value 102644603 | Price to Sales(TTM) 243.29 | ||
Enterprise Value to Revenue 100.04 | Enterprise Value to EBITDA -1.17 | Shares Outstanding 26002000 | Shares Floating 9390377 |
Shares Outstanding 26002000 | Shares Floating 9390377 | ||
Percent Insiders 59.85 | Percent Institutions 25.41 |
Upturn AI SWOT
Cartesian Therapeutics Inc.
Company Overview
History and Background
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering RNA cell therapy for autoimmune diseases. Founded to overcome limitations of traditional cell therapies, it engineers patient cells with RNA to enhance therapeutic efficacy and safety.
Core Business Areas
- RNA Armored Cell Therapy (rACT): Focuses on developing engineered cell therapies using RNA to treat autoimmune diseases. Cartesian's technology platform enables precise control and modulation of cell function, enhancing efficacy and safety profiles.
Leadership and Structure
Details on leadership and specific organizational structure are not readily available in detail beyond standard biotech company structure and publicly announced executives.
Top Products and Market Share
Key Offerings
- Descartes-08 (rACT-like BCMA): An autologous RNA-engineered CAR-T cell therapy for multiple myeloma. While direct market share isn't yet applicable as the product is still in clinical trials, it is positioned to compete with existing BCMA-targeted therapies. Competitors include Bristol Myers Squibb (Abecma) and Johnson & Johnson (Carvykti).
- Descartes-30 (rACT-like Rheumatoid Arthritis): An autologous RNA-engineered CAR-T cell therapy for rheumatoid arthritis. Similar to Descartes-08, market share is not applicable yet due to clinical trial phase. Competitors include AbbVie (Humira), Amgen (Enbrel), and Johnson & Johnson (Remicade).
Market Dynamics
Industry Overview
The autoimmune disease treatment market is substantial and growing, with increasing demand for targeted therapies. The cell therapy market, specifically CAR-T cell therapies, are rapidly evolving, demonstrating efficacy in hematological malignancies and showing promise in solid tumors and autoimmune diseases. It's a competitive market with a high degree of innovation.
Positioning
Cartesian Therapeutics is positioned as an innovator in the RNA-engineered cell therapy space, specifically targeting autoimmune diseases. Its rACT platform offers potential advantages over traditional cell therapies, including improved control and reduced toxicity.
Total Addressable Market (TAM)
The total addressable market for autoimmune disease therapies is estimated to be in the hundreds of billions of dollars. The TAM specifically for cell therapies in autoimmune diseases is smaller but rapidly growing, likely reaching tens of billions of dollars. Cartesian is targeting a slice of this expanding market.
Upturn SWOT Analysis
Strengths
- Novel RNA-engineered cell therapy platform (rACT)
- Focus on autoimmune diseases with high unmet need
- Potential for improved safety and efficacy compared to traditional cell therapies
- Strong intellectual property position
Weaknesses
- Clinical stage company with no approved products
- High risk of clinical trial failure
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on single technology platform
Opportunities
- Successful clinical trial outcomes leading to regulatory approval
- Expansion of rACT platform to other autoimmune diseases
- Strategic partnerships with larger pharmaceutical companies
- Increased adoption of cell therapies for autoimmune diseases
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies and other cell therapy developers
- Regulatory hurdles and evolving guidelines for cell therapies
- High cost of cell therapy manufacturing and delivery
Competitors and Market Share
Key Competitors
- BMY
- JNJ
- ABBV
- AMGN
Competitive Landscape
Cartesian, prior to the acquisition, offered a novel approach in rACT. BMY and JNJ have the lead in BCMA therapies. ABBV and AMGN lead in the broader autoimmune market.
Major Acquisitions
Selecta Biosciences
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: Selecta BioSciences (SELB) acquired Cartesian Therapeutics (private entity) to broaden their portfolio, increase the pipeline, and to create a combined company focused on cell therapies. The price was paid in share of the merged company and other financial obligations which are not exactly known.
Growth Trajectory and Initiatives
Historical Growth: Cartesian's growth has been primarily focused on advancing its rACT platform through preclinical and clinical development. The company was acquired in March 2024.
Future Projections: Future growth projections are now tied to Selecta BioSciences (SELB) following the acquisition. This involves integrating Cartesian's rACT platform into Selecta's existing pipeline and exploring synergies between the two companies' technologies.
Recent Initiatives: Recent initiatives include advancing clinical trials for Descartes-08 and Descartes-30 and preparing for potential regulatory filings following Selecta Biosciences aquisition.
Summary
Cartesian Therapeutics was a clinical-stage biotech with a novel rACT platform for autoimmune diseases. Its acquisition by Selecta Biosciences presents both opportunities and risks as the company works to integrate the two entities. Cartesian has potential through it's rACT. Cartesian faced the challenges of the high cost of clinical research.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Analyst Reports
- SEC Filings (SELB)
Disclaimers:
The information provided is based on publicly available data and analyst estimates, which are subject to change. Market share data are estimates. This is not financial advice. The prior-private nature of Cartesian presents informational challenges.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cartesian Therapeutics Inc.
Exchange NASDAQ | Headquaters Frederick, MD, United States | ||
IPO Launch date 2016-06-22 | President, CEO & Director Dr. Carsten Brunn Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 66 | |
Full time employees 66 | |||
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.